Sotera Health earnings date
Sotera Health (SH5) Q3 2026 Earnings Report
DE:SH5 Q3 2026 EPS Results
- Actual EPS
- EUR 0.26
- Consensus EPS
- EUR 0.24
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- EUR 0.23
DE:SH5 Q3 2026 Revenue Results
- Actual Revenue
- EUR 290.89M
- Expected Revenue
- EUR 286.39M
- Beat/Miss
- Beat by +EUR 4.50M
- YoY Revenue Growth
- +4.36%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 3, 2026
Sotera Health's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was positive overall. The company reported solid consolidated revenue, EBITDA, earnings, cash flow, leverage, and margin performance, reaffirmed its 2026 outlook, and highlighted progress in operational execution, customer programs, facility investments, and balance sheet improvement. These positives were partly offset by medical device softness concentrated in Europe, expected fourth-quarter moderation, a decline in Nelson Labs margin, Nordion revenue and income declines tied to shipment timing and volume mix, and foreign exchange headwinds.
Sotera Health is reaffirming its 2026 constant currency revenue growth outlook of 5.25% to 6.75%, with reported revenue in the range of $1.233 billion to $1.25 billion, and its adjusted EBITDA outlook of 5.75% to 7.25% constant currency growth, with adjusted EBITDA in the range of $632 million to $641 million; these reported ranges incorporate an estimated 70-basis point foreign currency benefit for the full year, with foreign exchange anticipated to be a headwind of more than 100-basis points in the fourth quarter. Full year consolidated adjusted EBITDA margins are expected to be approximately flat versus last year, total company pricing is expected to be within the long term range of 3% to 4%, Sterigenics constant currency revenue growth is expected to be mid to high single digit, including approximately 6% in the fourth quarter, Nordion constant currency revenue growth is expected to be in the mid single digits, and Nelson Labs constant currency revenue growth is expected to be in the low to mid single digits; fourth quarter growth is expected to moderate from third quarter levels, and full year segment income margins are projected to be similar to year to date levels. Interest expense is expected to be in the range of $137 million to $140 million, the effective tax rate applicable to adjusted net income remains 27% to 28%, depreciation expense is expected to increase in 2026 modestly above the increase experienced in 2025, fully diluted share count is expected to be in the range of 289 million to 291 million, adjusted EPS is expected to be $0.95 to $1.01 per diluted share, capital expenditures are anticipated to be in the $200 million to $225 million range, net leverage ratio is expected to improve compared to 2025, and the outlook does not assume any M&A activity.
- Consolidated Revenue and EBITDA GrowthThird quarter revenue increased 4.4% to $325 million on both an as-reported and constant currency basis. Adjusted EBITDA increased 3.9% as reported and 4% in constant currency to $171 million, while adjusted EBITDA margin expanded sequentially by nearly 100 basis points to 52.5%.
- Improved Earnings and Interest ExpenseGAAP net income was $58 million, or $0.20 per diluted share. Adjusted EPS increased 12% year over year to $0.29 per diluted share. Third-quarter interest expense declined by $5 million to $34 million, driven by repricing actions and the prior year's $75 million term loan paydown.
- Strong Sterigenics PerformanceSterigenics revenue increased 8.5% to $209 million, or 8.2% in constant currency, driven by favorable pricing of 4.8%, volume and mix growth of 3.4%, and a foreign currency benefit of 30 basis points. Segment income increased 9.6% to $117 million, or 9.2% in constant currency, and segment income margin expanded 57 basis points to 56.1%.
- Nelson Labs Revenue GrowthNelson Labs revenue increased 8.8% to $61 million, or 9.2% in constant currency, driven by volume and mix growth of 6.6% and favorable pricing of 2.6%, partially offset by a 40-basis-point foreign currency headwind. Revenue exceeded expectations due in part to increased Expert Advisory Services activity.
- Nordion Margin Expansion and Earlier ShipmentsAlthough Nordion revenue declined, results came in ahead of expectations due to earlier-than-anticipated timing of certain shipments. The team delivered critical cobalt-60 shipments, expanded segment income margin by 71 basis points to 61.3%, and improved operational productivity while benefiting from favorable pricing.
- Customer Project Supporting Critical Healthcare ProductsNelson Labs quickly mobilized scientific and technical expertise to complete accelerated regulatory testing for a customer facing an urgent need involving a product used in a significant percentage of surgeries worldwide. Management stated that the work helped maintain availability of a critical healthcare product and supported tens of millions of patients.
- Reaffirmed 2026 Revenue and EBITDA OutlookThe company reaffirmed its 2026 outlook for constant currency revenue growth of 5.25% to 6.75%, reported revenue of $1.233 billion to $1.25 billion, constant currency adjusted EBITDA growth of 5.75% to 7.25%, and adjusted EBITDA of $632 million to $641 million.
- Segment Growth Expectations MaintainedManagement continues to expect Sterigenics to deliver mid to high single digit constant currency revenue growth in 2026. Nordion is now expected to deliver mid single digits constant currency revenue growth, while Nelson Labs is expected to deliver low to mid single digits constant currency revenue growth.
- Balance Sheet StrengtheningThe company generated $228 million of operating cash flow year to date, including $111 million in the third quarter. Net leverage improved to 2.9x as of September 30, 2026, within the long-term target range of 2x to 3x. Moody's recognized the progress with a credit rating upgrade in early October.
- Investment in Capacity and FacilitiesCapital expenditures totaled $105 million during the first nine months, including $53 million in the third quarter. Spending supported Sterigenics capacity expansions, EO facility upgrades, Nordion cobalt-60 development initiatives, and completion of a new state-of-the-art clean room at the Salt Lake City laboratory.
- Progress on EO Facility EnhancementsManagement stated that the EO facility enhancements remain on track for completion in the fourth quarter or the first quarter of 2027.
- Cross-Business-Unit Selling OpportunityApproximately 70% of Sterigenics and Nelson Labs revenue comes from shared customers. Management said it has initiatives in place to penetrate these accounts with the full offering and expects Nelson Labs, including core lab testing, to benefit from the cross-business-unit strategy.
- Outsourced Customer Program On TrackThe previously discussed outsourced customer program is on track, going well, and contributed to third-quarter growth. Management expects it to contribute to fourth-quarter growth as well, while the commercial team continues to build a pipeline that includes additional outsourcing opportunities.
- North Carolina X-Ray Facility PipelineThe North Carolina X-ray facility contributed to third-quarter growth. Despite some fourth-quarter softness, management said it has a very strong pipeline and remains confident that utilization will continue to improve.
- Capital Allocation and Free Cash Flow ObjectivesManagement continues to prioritize organic growth investments and strategic M&A opportunities focused on sterilization services, while also evaluating share repurchases and debt paydown. The company remains on track to deliver its Investor Day objective of $500 million to $600 million of free cash flow over the stated period and expects a meaningful step down in capital expenditures next year.
- 2026 Earnings and Financial AssumptionsThe company expects full-year adjusted EPS of $0.95 to $1.01 per diluted share, interest expense of $137 million to $140 million, an effective tax rate applicable to adjusted net income of 27% to 28%, a fully diluted share count of 289 million to 291 million, and capital expenditures of $200 million to $225 million. The outlook assumes total-company pricing within the long-term range of 3% to 4% and does not assume M&A activity.
- Litigation Defense Strategy and Case MilestonesManagement stated that it has a strategy to defend the company and is executing against it. An appellate decision in Georgia is expected in spring 2027, first trials in California are scheduled for January and April 2027, and Illinois cases have been assigned to a single judge and are in pretrial proceedings.
DE:SH5 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | 0.23- | 0.23 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | 0.240.26 | 0.23 | 11.54% (+0.03) | |
| Aug 06, 2026 | 2026 (Q2) | 0.210.23 | 0.18 | 30.00% (+0.05) | |
| May 05, 2026 | 2026 (Q1) | 0.160.16 | 0.13 | 28.57% (+0.04) | |
| Feb 24, 2026 | 2025 (Q4) | 0.220.23 | 0.19 | 23.81% (+0.04) | |
| Nov 04, 2025 | 2025 (Q3) | 0.200.23 | 0.15 | 52.94% (+0.08) | |
| Aug 08, 2025 | 2025 (Q2) | 0.150.18 | 0.17 | 5.26% (+0.01) | |
| May 01, 2025 | 2025 (Q1) | 0.110.13 | 0.12 | 7.69% (+0.01) | |
| Feb 27, 2025 | 2024 (Q4) | 0.180.19 | 0.23 | -19.23% (-0.04) | |
| Nov 05, 2024 | 2024 (Q3) | 0.160.15 | 0.19 | -19.05% (-0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


